A comparative study of the effect of platelet-rich plasma injection with 5% minoxidil solution versus 5% minoxidil solution in the treatment of androgenetic hair loss

A comparative study of platelet rich plasma injection with 5% minoxidil solution versus 5% minoxidil solution in the treatment of androgenetic hair loss

Clinical trial with control group, with parallel groups, double-blind, randomized, phase 1 and 2 on 40 patients, with simple randomization method.

Basic information including demographic and clinical information is collected through a questionnaire and when the patients visit the skin clinic of Imam Khomeini Hospital in Ahvaz, and the patients are randomly divided into 2 groups of 20 people. The first group is treated with platelet-rich plasma along with 5% minoxidil solution, the second group is treated with 5% minoxidil solution. Patients will receive medicine at 0.1 cc per centimeter for 4 weeks for 3 months.

Inclusion criteria: Men with hereditary hormonal hair loss, age 18 years or older and less than 50 years, Hamilton score 2 to 5, full patient consent to participate in the project. Exclusion criteria: platelet disorders or thrombocytopenia, patients receiving anticoagulants, and patients with malignancy.

Patients are randomly divided into 2 groups of 20 people. The first group is treated with platelet-rich plasma along with 5% minoxidil solution, the second group is treated with 5% minoxidil solution.

Hair follicle density per unit area, hair follicle thickness, hair follicle cuticle condition, hair follicle length

Patients with eligibility criteria will be divided into two groups using a randomized block design. An online website (https://www.sealedenvelope.com) is used to generate a random list based on the desired sample size and block size of 4. After creating a list, each patient will be identified with a unique code throughout the study. 20 people are selected for the first intervention group and 20 people for the second intervention group. Then, each number is written on the drug container, which is the same for both groups, and it will be given to the patients by someone other than the interventionist, while the patients are not aware of the contents of the container.

In this study, the participant, researcher, doctor, interventionist and evaluator will be unaware of the type of drug until the end of the study. The composition of this medicine is poured into similar containers and they cannot be distinguished from each other in terms of color and smell.

There is no further information